StockData
Parabilis Medicines, Inc. logo

Parabilis Medicines, Inc. (PBLS) stock

PBLSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026
$28.25−0.20 (-0.70%)

Close on Nov 17, 2026Market cap $3.49BP/E –Yield –

Parabilis Medicines r&d expenses

Research and development expenses are spending on new products and technology.

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$39.38M–
Q2 FY2025Jun 30, 2025$30.13M–

More Parabilis Medicines figures

See a number that looks wrong?